Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Pharmacokinetics of Antiepileptics in Patients on CRRT

NCT03632915 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the study is to measure levels of any of the following AEDs (levetiracetam, phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and optimize dosing strategies in patients on CRRT.

Interventions

  • DRUG Ketamine
  • DRUG Levetiracetam
  • DRUG Lacosamide
  • DRUG Phenytoin
  • DRUG Phenobarbital

Study Locations (1)

Maryland

  • University of Maryland Medical Center — Baltimore

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2017-11-20
Est. Completion 2019-12-31

Sponsor

University of Maryland, Baltimore

559 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03632915

The ClinicalTrials.gov registry entry for NCT03632915 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 559 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 5 interventions — of which Ketamine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03632915 reports 1 study location spanning 1 distinct geographic area — top geographies include Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03632915 about?

NCT03632915 is a clinical study titled "Pharmacokinetics of Antiepileptics in Patients on CRRT". The purpose of the study is to measure levels of any of the following AEDs (levetiracetam, phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and optimize dosing strategies in p...

What is the current status of trial NCT03632915?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2017-11-20. Estimated completion is 2019-12-31.

What conditions does trial NCT03632915 study?

This clinical trial studies the following conditions: Acute Kidney Injury, Pharmacokinetics, Renal Insufficiency, Renal Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03632915?

The interventions under investigation include: Ketamine (DRUG), Levetiracetam (DRUG), Lacosamide (DRUG), Phenytoin (DRUG), Phenobarbital (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03632915?

This trial is sponsored by University of Maryland, Baltimore, which has 559 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03632915 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial